Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that the Canadian authorities issued a patent for the drug candidate CS1:s second patent family on Tuesday April 9. This strengthens and expands the immaterial rights (IPR) for Cereno’s drug candidate CS1, which is currently in clinical Phase II development as a treatment of the rare disease Pulmonary Arterial Hypertension (PAH).

“I am pleased to announce that we have secured further immaterial rights for the drug candidate CS1 in Canada, a large and important pharmaceutical market. CS1:s expanding patent portfolio, together with the clinical documentation to be delivered from the Phase II study targeted for completion in Q3, are important building blocks for our exciting therapeutic and commercial potential of CS1 in the PAH market”, said Sten R. Sörensen, CEO, Cereno Scientific.

The second patent family is titled “Valproic Acid for the Treatment or Prevention of Pathological Conditions Associated with Excess Fibrin Deposition and/or Thrombus Formation" and has been issued patent number 2964041. The patent is valid through 2035, with the option to extend it for up to five years. The second patent family previously obtained patents in Australia, Canada, Europe, Japan, Israel, Malaysia, Mexico, Russia and USA.

About HDAC inhibitor CS1

Cereno Scientific has during the last few months reported positive findings from the ongoing study suggesting a potential clinical benefit of drug candidate CS1 in patients with the severe rare disease PAH. Study completion and topline results are expected during Q3 2024. On January 30, Cereno was granted approval by the FDA for Expanded Access, sometimes called “Compassionate Use”, for CS1 to use in an extension of the ongoing Phase II trial evaluating CS1 in PAH. This is an important milestone on our path toward making a difference for patients with the deadly rare disease PAH.

For further information, please contact:

Henrik Westdahl, Director IR & Communications

Email: henrik.westdahl@cerenoscientific.com

Phone: +46 70-817 59 96

Sten R. Sörensen, CEO

Email: sten.sorensen@cerenoscientific.com

Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific develops innovative treatments for rare and common cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q3 2024. Since January 2024, we are delighted that the FDA´s Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.